JP2024510504A5 - - Google Patents

Info

Publication number
JP2024510504A5
JP2024510504A5 JP2023557370A JP2023557370A JP2024510504A5 JP 2024510504 A5 JP2024510504 A5 JP 2024510504A5 JP 2023557370 A JP2023557370 A JP 2023557370A JP 2023557370 A JP2023557370 A JP 2023557370A JP 2024510504 A5 JP2024510504 A5 JP 2024510504A5
Authority
JP
Japan
Prior art keywords
independently selected
nitrogen
sulfur
oxygen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020527 external-priority patent/WO2022197789A1/en
Publication of JP2024510504A publication Critical patent/JP2024510504A/ja
Publication of JP2024510504A5 publication Critical patent/JP2024510504A5/ja
Pending legal-status Critical Current

Links

JP2023557370A 2021-03-17 2022-03-16 血漿カリクレインの多環式インヒビター Pending JP2024510504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162483P 2021-03-17 2021-03-17
US63/162,483 2021-03-17
PCT/US2022/020527 WO2022197789A1 (en) 2021-03-17 2022-03-16 Polycyclic inhibitors of plasma kallikrein

Publications (2)

Publication Number Publication Date
JP2024510504A JP2024510504A (ja) 2024-03-07
JP2024510504A5 true JP2024510504A5 (enExample) 2025-03-25

Family

ID=81328648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557370A Pending JP2024510504A (ja) 2021-03-17 2022-03-16 血漿カリクレインの多環式インヒビター

Country Status (5)

Country Link
US (1) US20240199613A1 (enExample)
EP (1) EP4308564A1 (enExample)
JP (1) JP2024510504A (enExample)
CN (1) CN117355523A (enExample)
WO (1) WO2022197789A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN118239959A (zh) * 2022-12-23 2024-06-25 上海深势唯思科技有限责任公司 环丙烷类tlr7和8抑制剂及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
JP2008501707A (ja) * 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2013052526A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
US20150182490A1 (en) * 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN104059069B (zh) * 2013-08-22 2016-08-10 北京康立生医药技术开发有限公司 一种替卡格雷的制备方法
WO2015164308A1 (en) * 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途

Similar Documents

Publication Publication Date Title
JP2022548696A5 (enExample)
TW536534B (en) Difluoroprostaglandin derivatives and pharmaceutical composition comprising them
JP2024516073A5 (enExample)
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
JP5596680B2 (ja) 経口抗がん製剤
JP2024510503A5 (enExample)
JP2020525442A5 (enExample)
JP2020510010A5 (enExample)
JP2018504437A5 (enExample)
DE69636086T2 (de) Sauerstoff enthaltende heterocyclische verbindungen
RU2016115934A (ru) Конденсированное гетероциклическое соединение, способ его получения, его фармацевтическая композиция и применения
PT2688873E (pt) Compostos de bis(fluoroalquil)-1,4-benzodiazepinona
CA2479103A1 (en) 1-azabicyclic n-biarylamides with affinity for the alpha7 nicotinic acetylcholine receptor
RU2005137360A (ru) Органические соединения
JP2024512497A5 (enExample)
JP2024510502A5 (enExample)
JP2021512132A (ja) 置換イミダゾールカルボン酸エステル系誘導体およびその使用
EA003360B1 (ru) Производные мононитрата изосорбида и их использование в качестве сосудорасширяющих агентов с пониженной толерантностью
JP2025527291A5 (enExample)
CN114286823B (zh) 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途
ES2753874T3 (es) Cristales de solvato novedosos
EA032872B1 (ru) Макроциклические ингибиторы rip2-киназы
JPS59204189A (ja) ジヒドロピリジル環状イミデ−トエステル
JP2023503672A (ja) 縮合ピリジン環誘導体、その調製方法及びその医薬的応用
JPS6092267A (ja) カルシウムチヤンネル遮断剤として有用な置換ジヒドロアゼピン